Cox Gerard, Miller John D, McWilliams Annette, Fitzgerald J Mark, Lam Stephen
M.B., Firestone Institute for Respiratory Health-T2123, St. Joseph's Healthcare, 50 Charlton Avenue, East Hamilton, ON L8N 4A6, Canada.
Am J Respir Crit Care Med. 2006 May 1;173(9):965-9. doi: 10.1164/rccm.200507-1162OC. Epub 2006 Feb 2.
Bronchial thermoplasty (BT) reduces the potential for smooth muscle-mediated bronchoconstriction by reducing the mass of smooth muscle in the walls of conducting airways.
This study was conducted to examine the safety and impact on lung function and airway responsiveness of BT over 2 yr.
The safety of BT was studied in 16 subjects with mild to moderate asthma. Baseline and 12-wk post-treatment measurements included spirometry, methacholine challenge, daily diary recordings of peak flow, symptoms, and medication usage. Subjects completed follow-up evaluations at 12 wk, 1 yr, and 2 yr.
The procedure was well tolerated; side effects were transient and typical of what is commonly observed after bronchoscopy. All subjects demonstrated improvement in airway responsiveness. The mean PC(20) increased by 2.37 +/- 1.72 (p < 0.001), 2.77 +/- 1.53 (p = 0.007), and 2.64 +/- 1.52 doublings (p < 0.001), at 12 wk, 1 yr, and 2 yr post-procedure, respectively. Data from daily diaries collected for 12 wk indicated significant improvements over baseline in symptom-free days (p = 0.015), morning peak flow (p = 0.01), and evening peak flow (p < or = 0.007). Spirometry measurements remained stable throughout the study period.
BT is well tolerated in patients with asthma and results in decreased airway hyperresponsiveness that persists for at least 2 yr.
支气管热成形术(BT)通过减少传导气道壁平滑肌的质量,降低平滑肌介导的支气管收缩的可能性。
本研究旨在探讨BT在2年期间的安全性以及对肺功能和气道反应性的影响。
对16例轻至中度哮喘患者进行BT安全性研究。基线和治疗后12周的测量包括肺量计检查、乙酰甲胆碱激发试验、每日峰值流量、症状和药物使用情况的日记记录。受试者在12周、1年和2年时完成随访评估。
该手术耐受性良好;副作用是短暂的,是支气管镜检查后常见的典型情况。所有受试者的气道反应性均有改善。术后12周、1年和2年时,平均PC(20)分别增加2.37±1.72(p<0.001)、2.77±1.53(p = 0.007)和2.64±1.52倍(p<0.001)。收集的12周每日日记数据表明,无症状天数(p = 0.015)、早晨峰值流量(p = 0.01)和晚上峰值流量(p≤0.007)较基线有显著改善。在整个研究期间,肺量计测量结果保持稳定。
哮喘患者对BT耐受性良好,且气道高反应性降低,这种效果至少持续2年。